2Livermore DM, Williams JD. β-lactams: mode of action and mechanisms of bacterial resistance. In: Lorian V, eds. Antibiotics in laboratory medicine. 4th ed. Baltimore:Williams & Wilkins, 1996. 502-578.
3Sanders CC. β-lactamase of gram negative bacteria: new challenges for new drugs. Clin Infect Dis, 1992,14:1089-1099.
4Naumiuk L, Samet A, Dziemaszkiewicz E. Cefepime in vitro activity against derepressed extended-spectrum β-lactamase(ESBL)-producing and non-ESBL-producing Enterobacter cloacae by a disc diffusion method. J Antimicrob Chemother, 2001,48:321-322.
5National Committee for Clinical Laboratory Standards. Performance standards for antimicrobial susceptibility testing. 9th informational supplement(M100-S9). Wayne:NCCLS,1999.
6Coudron PE,Moland ES, Thomson KS. Occurrence and detection of AmpC β-lactamases among Escherichia coli,Klebsiella pneumoniae,and Proteus mirabilis isolates at a veterans medical center. J Clin Microbiol, 2000, 38:1791-1796.
7Tzelepi E, Giakkoupi P, Sofianou D, et al. Detection of extended-spectrum β-lactamases in clinical isolates of Enterobacter cloacae and Enterobacter aerogenes. J Clin Microbiol, 2000,38:542-546.
8Chanal C, Sirot D, Romaszko JP, et al. Survey of extended-spectrum β-lactamases among Enterobacteriaceae. J Antimicrob Chemother, 1996, 38:127-132.
9Coudron PE,Moland ES, Sanders CC. Occurrence and detection of extended-spectrum β-lactamases in members of the family Enterobacteriaceae at a veterans medical center: seek and you may find. J Clin Microbiol, 1997, 35:2593-2597.
10Bradford P A，Antimicrob Agents Chemother，1998年，42卷，1980页
